Hayley M. Sabol
Graduate Assistant
Also affiliated: Fox Chase Cancer Center (2026); Temple University (2026)
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Hayley M. Sabol's research focuses on the signaling pathways involved in multiple myeloma, particularly the role of Notch signaling in the tumor microenvironment and its impact on bone destruction. Her work investigates how interactions between myeloma cells and osteocytes, the bone-forming cells, contribute to disease progression and treatment resistance.
Sabol has received federal funding from the NIH/National Cancer Institute for her work targeting Notch3 for multiple myeloma treatment. Her research group has published studies on the mechanisms by which Notch inhibitors can decrease tumor growth and bone destruction while minimizing side effects. Additional research explores novel signaling axes, such as CCL3-HMGB1 and NOTCH3-CXCL12, that regulate osteocyte function and promote chemoresistance in multiple myeloma. Her work also examines therapeutic strategies, including the targeting of p62 ZZ domain and sclerostin inhibition, to enhance anti-tumor effects and restore bone health in patients with multiple myeloma.
Her scholarship metrics include an h-index of 6, with 82 total publications and 132 total citations. Sabol collaborates extensively with researchers at the University of Arkansas for Medical Sciences, including Sharmin Khan, Aric Anloague, Olivia Reyes-Castro, and Japneet Kaur, with whom she shares numerous publications.
Metrics
- h-index: 6
- Publications: 82
- Citations: 132
Positions
-
Graduate Assistant publications 2021–2026University of Arkansas for Medical Sciences Institution web page
Selected Publications
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells (2026)
-
Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition (2025)
-
Abstract 5099: Notch inhibition as a therapeutic approach to eliminate dormant cancer cells in multiple myeloma (2025)
Federal Grants 1 $39,248 total
Collaboration Network
Top Collaborators
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- The multifunctional role of Notch signaling in multiple myeloma
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
Showing 5 of 18 shared publications
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
Showing 5 of 13 shared publications
- Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma
- Abstract 5672: Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
Showing 5 of 10 shared publications
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
Showing 5 of 10 shared publications
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
Showing 5 of 9 shared publications
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
- Data from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Abstract 5099: Notch inhibition as a therapeutic approach to eliminate dormant cancer cells in multiple myeloma
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
Showing 5 of 9 shared publications
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
Showing 5 of 8 shared publications
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
- Abstract 5675: Pathological crosstalk between osteocytes and breast cancer cells in bone metastasis
Showing 5 of 7 shared publications
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
Showing 5 of 7 shared publications
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
Showing 5 of 7 shared publications
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
- Abstract 5099: Notch inhibition as a therapeutic approach to eliminate dormant cancer cells in multiple myeloma
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
Showing 5 of 7 shared publications
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
- Abstract 5672: Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
Showing 5 of 6 shared publications
- Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis
- A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis
- Healing of lytic lesions and restoration of bone health in multiple myeloma through sclerostin inhibition
Showing 5 of 6 shared publications
- Abstract 5099: Notch inhibition as a therapeutic approach to eliminate dormant cancer cells in multiple myeloma
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
- Additional file 1 of Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells
Showing 5 of 6 shared publications
- Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
- Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma
- Abstract 5672: Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
- Data from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity
Similar Researchers
Based on overlapping research topics